Home PR Newswire
Monday, September 7, 2026
30
C
Bengaluru
Hot topics
Why Pharma Sales Enablement Is a Necessity for Success
Challenging times lay ahead for the sales departments in the pharma industry. The COVID-19 pandemic will surely not be the first disruption, as recent geopolitical tensions, and economic turmoil show. Agile and adaptive sales enablement is thus a must-have in the coming months and years.
“Sales at Any Cost” is Not Sustainable in the Long Run
For commercial organisations, profits are important. But it cannot be 'at any cost' and certainly not at the cost of human life. As healthcare providers helping to mitigate the pain and misery of millions of human beings, we need to remember that charity begins at home.
Philippe Gautron Takes on Role as Senior Vice President & Business Head – APAC at Glenmark Pharmaceuticals
Ho Chi Minh City, Vietnam, March 2026 — Glenmark...
A Social Experiment
Articles by K. Hariram, Vivek Hattangadi, Hanno Wolfram, RB Balakrishna and Rajiv Jayaraman
Meril Life Sciences is India’s Top Medtech Company
India's MedTech Mavericks: The Profitability Paradox: Balancing Rapid Growth...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
Hot topics
7 Transitions in Leadership for Indian Pharma Leaders
The rapid pace of change, which began in 2020...
What Can Pharma Learn about Customer Experience from Other Industries?
In today's competitive retail world, lower pricing and creative...
Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?
C-Suite Executive Summary
India stands at a pivotal juncture in...
Indian Pharma’s November 2025: How GLP-1s Rewired the Market
Indian pharma wrapped up November 2025 with serious velocity....
Boehringer Ingelheim India focuses on partnerships in NCD management
Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
RPG-Raghava and Lessons From a Decade of Indian Pharma M&A
RPG Active Pharma’s agreement to acquire the API and...
Pharmacy of the World Pricing Paradox
India occupies an extraordinary position in global pharmaceuticals. It...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
Newsletter
Get important news delivered directly to your inbox and stay connected!